Nab-paclitaxel-related cystoid macular edema is a rare ophthalmic adverse drug reaction. We present a 54-year-old woman with metastatic hormone receptor positive, HER-2 negative breast carcinoma who developed profound bilateral vision loss after the seventh cycle of nab-paclitaxel treatment. Optical coherence tomography and macula microperimetry demonstrated macular edema and decreased threshold sensitivity, respectively. Cessation of nab-paclitaxel improved structural and functional vision after 4 weeks. The introduction of topical dorzolamide 1% in one eye demonstrated further rapid resolution of edema. We demonstrate the objective and subjective visual changes and recovery of nab-paclitaxel-related cystoid macular edema. [ Ophthalmic Surg Lasers Imaging Retina 2024;55:408-411.] .
Keyphrases
- optical coherence tomography
- diabetic retinopathy
- advanced non small cell lung cancer
- adverse drug
- case report
- optic nerve
- cataract surgery
- small cell lung cancer
- age related macular degeneration
- squamous cell carcinoma
- chemotherapy induced
- emergency department
- high resolution
- physical activity
- epidermal growth factor receptor
- mass spectrometry
- electronic health record
- intellectual disability
- depressive symptoms
- sleep quality
- smoking cessation